Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cypher Genomics, Illumina Enter Biomarker Agreement

Published: Saturday, July 26, 2014
Last Updated: Saturday, July 26, 2014
Bookmark and Share
Co-promotion agreement to facilitate genomic biomarker discovery.

Cypher Genomics, Inc. has announced a co-promotion agreement with Illumina to facilitate the development of genomic-based biomarkers from whole genome sequence data for precision medicine and clinical trials.

Cypher Genomics and Illumina will jointly offer pharmaceutical companies, through Illumina's sales force, a solution including Illumina's market leading sequencing technology, the NextBio platform for data analytics and storage, and Cypher Genomics' biomarker discovery service, called Coral™.

Cypher Genomics technology reduces the signal-to-noise in genomic information to uncover important biomarkers in sample sizes typical of early stage drug development studies.

"Cypher Genomics' biomarker discovery service is a perfect complement to Illumina's whole genome sequencing and our NextBio analytics platform," said Nick Naclerio, SVP Corporate Development and General Manager Enterprise Informatics of Illumina. "We look forward to working with Cypher Genomics to provide our mutual customers with the sequencing, data interpretation, and data mining they require for biomarker discovery with whole genome data."

"We founded Cypher Genomics to transform the practice of medicine through fast and accurate genome interpretation. Cypher Genomics' biomarker discovery service, Coral™, includes technology that has a proven track record of success with pharmaceutical companies to discover the genetic basis of response to drug therapy," states Ashley Van Zeeland, Ph.D., co-founder and chief executive officer of Cypher Genomics.

The benefits of biomarker discovery to deliver precision medicine is clear - better tools that can match therapies to patients not only improves clinical outcomes but also reduce clinical trial sizes, which can accelerate time to market for life-saving therapies.

Many desire to look beyond biomarker panels to the whole genome, but biomarker discovery based on whole genome data generally has not been feasible due to the lack of statistical power within the small sample sizes of early clinical studies.

Cypher's genomic analysis platform provides highly accurate genome annotations combined with advanced statistical techniques to enable biomarker discovery studies with sample sizes in the hundreds, reflecting the reality of many Phase 2 clinical trials.

Adam Simpson, president and chief operating officer of Cypher Genomics, added, "Working with Illumina to offer best-in-class sequencing and analysis to pharmaceutical companies enables acceleration of their personalized drug development efforts and will ultimately help deliver on the promise of precision medicine."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cypher Genomics And Sequenom Announce Development Agreement
Sequenom to apply Cypher's Mantis technology for advanced genome interpretation in NIPT.
Friday, January 23, 2015
Scientific News
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Autism and Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Flowering Regulation Mechanism Discovered
Monash researchers have discovered a new mechanism that enables plants to regulate their flowering in response to raised temperatures.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Nanoparticles Present Sustainable Way to Grow Food Crops
Nanoparticle technology can help reduce the need for fertilizer, creating a more sustainable way to grow crops such as mung beans.
How Scientists Use DNA to Track Disease Outbreaks
They’re the top questions on everyone’s mind when a new disease outbreak happens: where did the virus come from? When did this happen? How long has it been spreading in a particular country or group of people?
Genetic Risk Factors of Disparate Diseases Share Similar Biological Underpinnings
Penn Institute for Biomedical Informatics and colleagues identify "roadmap" of disease mechanisms to identify candidate drug targets.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!